LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 1235 | 4679 | 4929 | 0.9492 | 0.9485 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 1235 | 4471 | 4474 | 0.9992 | 0.9991 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 1235 | 4454 | 4578 | 0.9728 | 0.9710 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 1235 | 4501 | 4929 | 0.9131 | 0.9110 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 1235 | 4005 | 4474 | 0.8950 | 0.8840 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 1235 | 4122 | 4578 | 0.9003 | 0.8918 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 1235 | 4034 | 4929 | 0.8184 | 0.8089 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1235 | 2245 | 4474 | 0.5017 | 0.3793 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1235 | 2076 | 4578 | 0.4534 | 0.3159 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1235 | 2282 | 4929 | 0.4630 | 0.3597 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 1235 | 1456 | 4474 | 0.3254 | 0.0923 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 1235 | 1396 | 4578 | 0.3049 | 0.0666 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 1235 | 1411 | 4929 | 0.2863 | 0.0686 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 1235 | 926 | 4474 | 0.2069 | -0.1441 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 1235 | 920 | 4578 | 0.2009 | -0.1447 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 1235 | 971 | 4929 | 0.1970 | -0.1139 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 1235 | 4421 | 4355 | 1.0149 | 1.0164 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 1235 | 4228 | 4277 | 0.9885 | 0.9871 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 1235 | 4342 | 4583 | 0.9473 | 0.9436 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 1235 | 3706 | 4355 | 0.8508 | 0.8299 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 1235 | 3414 | 4277 | 0.7982 | 0.7635 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 1235 | 4257 | 4583 | 0.9288 | 0.9234 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 1235 | 3687 | 4355 | 0.8464 | 0.8247 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 1235 | 3618 | 4277 | 0.8459 | 0.8215 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 3 | D04 | 72 | hr | 1235 | 3758 | 4583 | 0.8199 | 0.8006 |